Christof Scheid
- Hematology top 1%
- Oncology top 5%
- Molecular Biology
- Immunology top 5%
- Genetics top 5%
- Co-authors
- Udo HoltickMichael HallekSebastian TheurichMichael von Bergwelt‐BaildonJens ChemnitzAlexander Shimabukuro‐VornhagenNicole SkoetzJens M. Chemnitz
- Topics
- Multiple Myeloma Research and Treatments (49 papers)Hematopoietic Stem Cell Transplantation (37 papers)Protein Degradation and Inhibitors (23 papers)
- Cited by
- HematologyGeneticsTransplantation
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Christof Scheid
139 papers receiving 2.1k citations
Peers
Comparison fields: 5 of 110
- Hematology 1.1k
- Oncology 648
- Molecular Biology 578
- Immunology 472
- Genetics 340
Countries citing papers authored by Christof Scheid
This map shows the geographic impact of Christof Scheid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christof Scheid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christof Scheid more than expected).
Fields of papers citing papers by Christof Scheid
This network shows the impact of papers produced by Christof Scheid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christof Scheid. The network helps show where Christof Scheid may publish in the future.
Co-authorship network of co-authors of Christof Scheid
This figure shows the co-authorship network connecting the top 25 collaborators of Christof Scheid. A scholar is included among the top collaborators of Christof Scheid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christof Scheid. Christof Scheid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 1 | |
| 5 | 1 | |
| 6 | 1 | |
| 7 | 8 | |
| 8 | 8 | |
| 9 | 0 | |
| 10 | 13 | |
| 11 | 1 | |
| 12 | 6 | |
| 13 | 12 | |
| 14 | 7 | |
| 15 | COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110) | 2 |
| 16 | 6 | |
| 17 | 2 | |
| 18 | 28 | |
| 19 | 29 | |
| 20 | 42 |
About Christof Scheid
Christof Scheid is a scholar working on Hematology, Genetics and Oncology, having authored 149 papers that have together received 2.2k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (49 papers), Hematopoietic Stem Cell Transplantation (37 papers) and Protein Degradation and Inhibitors (23 papers). The work is most often cited by research in Hematology (1.1k citations), Genetics (340 citations) and Transplantation (73 citations). Christof Scheid has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Udo Holtick, Michael Hallek, Sebastian Theurich, Michael von Bergwelt‐Baildon, Jens Chemnitz, Alexander Shimabukuro‐Vornhagen, Nicole Skoetz, Jens M. Chemnitz, Peter L. Stern and Volker Diehl. Their work appears in journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.